Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Comment by d_trumpon Oct 23, 2015 5:27pm
148 Views
Post# 24222453

RE:Revised 2016 SP Target Regardless Of VRX Response

RE:Revised 2016 SP Target Regardless Of VRX Response
when2buy wrote:
Unfortunately, even a vindication of VRX's position and business practices will not return the stock to price levels recently seen. I have owned Short attack stocks in the past and rarely does proving accusations wrong bring the stocks back to previous highs.

Regardless of recent allegations, VRX own CC suggests a greater emphasis on debt reduction and organic growth in 2016. Given this, analysts will be taking down earnings estimate substantially over the coming weeks. Current consensus suggests a 39% increase in cash earnings in 2016 which seems unattainable under the current governmental & institutional scrutiny of pricing & acquisition strategies.

Given this, one can calculate a 12 month target price higher than today's but certainly not back to the glory days of $200+ as this was based on aggressive growth estimates and inflated growth multiple(s) of 20+ P/E.

We can only hope at this stage, the SP will stabilize through Monday's CC.

Continued GLTA, here


I agree, also VRX was never really worth $250-$350 because growth by acquisition should not be priced the same as organic growth - the market did not reflect this reality because of the street's infatuation with Mike Pearson.  This will rebound somewhat however the street will now be demanding more realistic metrics - the days of astronomical PE's and Price to NBV are over.

<< Previous
Bullboard Posts
Next >>